



Llama
Immunization




VHH Cloning &
Phage Library
Construction




Target Panning

High Throughput
Cell Binding
Screen




CAR-T Cloning

High Throughput
CAR-J Screening
(+ and - targets)






Fine tune
Signaling
Through Hinge
Truncation









In vitro and *in vivo* confirmatory testing
using primary human CAR-T cells


Supplementary figure 1: Workflow diagram for discovery and optimization for novel tumour selective CAR constructs




Supplemental Figure 2: EGFR-CAR-Jurkat and primary CAR-T cells can respond to EGFR-positive cells with a wide range of antigen expression




Supplemental Figure 3: CAR Surface expression is not altered with hinge domain modification



Supplemental Figure 4: Gating scheme for CAR-Jurkat target cell doublet formation assay




Supplemental Figure 5: CAR Surface expression in primary CAR-T cells does not correlate with hinge length




Supplemental Figure 6: Hinge truncation results in progressively reduced EGFR-sdCAR antigen responses and enhanced selectivity for EGFR-high targets



Tumour Cell Growth



CAR-T Cell Expansion



SUPPLEMENTAL Figure 7: Hinge truncated CAR-T cells maintain selectivity for target overexpressing cells following re-challenge



Supplemental Figure 8: Hinge truncated CAR-T cells maintain enhanced tumour selectivity in triple co-cultures with both healthy donor cells